Cytokine-targeted treatment in alopecia areata - new possibilities?
DOI:
https://doi.org/10.56782/pps.133Keywords:
alopecia areata, cytokines, treatmentAbstract
Alopecia areata is a form of non-scarring hair loss characterised by a recurrent and difficult-to-treat course. The aetiology of this disease is still incompletely understood. However, multiple immunological pathways and an abnormal cytokine profile in patients with alopecia areata have been described. There are many therapeutic options for patients with alopecia areata, including topical, intralesional or systemic corticosteroids, contact immunotherapy, phototherapy and non-corticosteroid immunosuppressive drugs such as cyclosporine, methotrexate or azathioprine. However, these treatments have limited efficacy and may be associated with side effects. In addition, Janus kinase inhibitors have been shown to cause metabolic disorders. Therefore, their use in patients with alopecia areata may be limited. Other cytokine-targeted therapies have been shown to be effective in alopecia areata, such as apremilast (a phosphodiesterase 4 inhibitor), ustekinumab (a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin 12 and 23), abatacept (a soluble fusion protein which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 to the modified Fc portion of human immunoglobulin G1), secukinumab (an IL-17A antagonist) and dupilumab (a monoclonal antibody that blocks interleukin 4 and interleukin 13). TNF inhibitors (such as infliximab, adalimumab and etanercept) have been described to be ineffective in alopecia areata. In addition, disease exacerbation after TNF therapy has been reported. Alefacept (an immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding part of human leukocyte function antigen-3 fused to the Fc part of human IgG1) and efalizumab (anti-CD11a monoclonal antibody) have not shown efficacy in alopecia areata. There are also isolated reports of alopecia areata after therapy with omalizumab (recombinant humanised monoclonal antibody anti-IgE), ixekizumab (inhibitor of IL-17A) and brodalumab (inhibitor of IL-17R).
Downloads
References
Pratt CH, King LE Jr, Messenger AG, Christiano AM, Sundberg JP. Alopecia areata. Nat Rev Dis Primers. 2017;3:17011. Published 2017 Mar 16. doi:10.1038/nrdp.2017.11 DOI: https://doi.org/10.1038/nrdp.2017.11
Juárez-Rendón KJ, Rivera Sánchez G, Reyes-López MÁ, et al. Alopecia Areata. Current situation and perspectives. Alopecia areata. Actualidad y perspectivas. Arch Argent Pediatr. 2017;115(6):e404-e411. doi:10.5546/aap.2017.eng.e404 DOI: https://doi.org/10.5546/aap.2017.e404
Craiglow BG, Tavares D, King BA. Topical Ruxolitinib for the Treatment of Alopecia Universalis. JAMA Dermatol 2016;152(4):490-1. doi:10.1001/jamadermatol.2015.4445 DOI: https://doi.org/10.1001/jamadermatol.2015.4445
Cortés G A, Mardones V F, Zemelman D V. Caracterización de las causas de alopecia infantil. Rev Chil Pediatr 2015;86(4):264-9. doi: 10.1016/j.rchipe.2015.06.015 DOI: https://doi.org/10.1016/j.rchipe.2015.06.015
Renert-Yuval Y, Guttman-Yassky E. The Changing Landscape of Alopecia Areata: The Therapeutic Paradigm. Adv Ther. 2017;34(7):1594-1609. doi:10.1007/s12325-017-0542-7 DOI: https://doi.org/10.1007/s12325-017-0542-7
Bertolini M, McElwee K, Gilhar A, Bulfone-Paus S, Paus R. Hair follicle immune privilege and its collapse in alopecia areata. Exp Dermatol. 2020;29(8):703-725. doi:10.1111/exd.14155 DOI: https://doi.org/10.1111/exd.14155
Fukuyama M, Ito T, Ohyama M. Alopecia areata: Current understanding of the pathophysiology and update on therapeutic approaches, featuring the Japanese Dermatological Association guidelines. J Dermatol. 2022;49(1):19-36. doi:10.1111/1346-8138.16207 DOI: https://doi.org/10.1111/1346-8138.16207
Pourang A, Mesinkovska NA. New and Emerging Therapies for Alopecia Areata. Drugs. 2020;80(7):635-646. doi:10.1007/s40265-020-01293-0 DOI: https://doi.org/10.1007/s40265-020-01293-0
Lee NR, Kim BK, Yoon NY, Lee SY, Ahn SY, Lee WS. Differences in Comorbidity Profiles between Early-Onset and Late-Onset Alopecia Areata Patients: A Retrospective Study of 871 Korean Patients. Ann Dermatol. 2014;26(6):722-726. doi:10.5021/ad.2014.26.6.722 DOI: https://doi.org/10.5021/ad.2014.26.6.722
Whiting DA. Histopathologic features of alopecia areata: a new look. Arch Dermatol. 2003;139(12):1555-1559. doi:10.1001/archderm.139.12.1555 DOI: https://doi.org/10.1001/archderm.139.12.1555
Harries MJ, Paus R. The pathogenesis of primary cicatricial alopecias. Am J Pathol. 2010;177(5):2152-2162. doi:10.2353/ajpath.2010.100454 DOI: https://doi.org/10.2353/ajpath.2010.100454
Ait Ourhroui M, Hassam B, Khoudri I. Traitement de la pelade par bolus oral mensuel de prednisone [Treatment of alopecia areata with prednisone in a once-monthly oral pulse]. Ann Dermatol Venereol. 2010;137(8-9):514-518. doi:10.1016/j.annder.2010.06.002 DOI: https://doi.org/10.1016/j.annder.2010.06.002
Macey J, Kitchen H, Aldhouse NVJ, et al. Dermatologist and Patient Perceptions of Treatment Success in Alopecia Areata and Evaluation of Clinical Outcome Assessments in Japan. Dermatol Ther (Heidelb). 2021;11(2):433-447. doi:10.1007/s13555-020-00477-6 DOI: https://doi.org/10.1007/s13555-020-00477-6
Malik K, Guttman-Yassky E. Cytokine Targeted Therapeutics for Alopecia Areata: Lessons from Atopic Dermatitis and Other Inflammatory Skin Diseases. J Investig Dermatol Symp Proc. 2018;19(1):S62-S64. doi:10.1016/j.jisp.2017.10.005 DOI: https://doi.org/10.1016/j.jisp.2017.10.005
Wang EHC, Sallee BN, Tejeda CI, Christiano AM. JAK Inhibitors for Treatment of Alopecia Areata. J Invest Dermatol. 2018;138(9):1911-1916. doi:10.1016/j.jid.2018.05.027 DOI: https://doi.org/10.1016/j.jid.2018.05.027
Gilhar A, Keren A, Paus R. JAK inhibitors and alopecia areata. Lancet. 2019;393(10169):318-319. doi:10.1016/S0140-6736(18)32987-8 DOI: https://doi.org/10.1016/S0140-6736(18)32987-8
Li H, Zuo J, Tang W. Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases. Front Pharmacol. 2018;9:1048. Published 2018 Oct 17. doi:10.3389/fphar.2018.01048
Li H, Zuo J, Tang W. Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases. Front Pharmacol. 2018;9:1048. Published 2018 Oct 17. doi:10.3389/fphar.2018.01048 DOI: https://doi.org/10.3389/fphar.2018.01048
Keren A, Shemer A, Ullmann Y, Paus R, Gilhar A. The PDE4 inhibitor, apremilast, suppresses experimentally induced alopecia areata in human skin in vivo. J Dermatol Sci. 2015;77(1):74-76. doi:10.1016/j.jdermsci.2014.11.009 DOI: https://doi.org/10.1016/j.jdermsci.2014.11.009
Liu LY, King BA. Lack of efficacy of apremilast in 9 patients with severe alopecia areata. J Am Acad Dermatol. 2017;77(4):773-774. doi:10.1016/j.jaad.2017.05.034 DOI: https://doi.org/10.1016/j.jaad.2017.05.034
Mikhaylov D, Pavel A, Yao C, et al. A randomized placebo-controlled single-center pilot study of the safety and efficacy of apremilast in subjects with moderate-to-severe alopecia areata. Arch Dermatol Res. 2019;311(1):29-36. doi:10.1007/s00403-018-1876-y DOI: https://doi.org/10.1007/s00403-018-1876-y
Magdaleno-Tapial J, Valenzuela-Oñate C, Sánchez-Carazo JL, Alegre-de Miquel V. Improvement of alopecia areata with apremilast. Australas J Dermatol. 2019;60(2):144-145. doi:10.1111/ajd.12934 DOI: https://doi.org/10.1111/ajd.12934
López, S.R., Castro, C.G., Calzada, P.M., & Segura, P.C.. Alopecia Areata and Severe Psoriasis Successfully Treated with Apremilast. Archives of Clinical Dermatology. 2017;1(1):2 doi: 10.24983/scitemed.acd.2017.00033
Taneja N, Gupta S. Apremilast is efficacious in refractory alopecia areata. J Dermatolog Treat. 2020;31(7):727-729. doi:10.1080/09546634.2019.1616046 DOI: https://doi.org/10.1080/09546634.2019.1616046
Estébanez A, Estébanez N, Martín JM, Montesinos E. Apremilast in Refractory Alopecia Areata. Int J Trichology. 2019;11(5):213-215. doi:10.4103/ijt.ijt_59_19 DOI: https://doi.org/10.4103/ijt.ijt_59_19
Sakakibara M, Shimoyama H, Nomura M, et al. Efficacy of the phosphodiesterase-4 inhibitor, apremilast, in a patient with severe alopecia areata. Eur J Dermatol. 2019;29(4):436-437. doi:10.1684/ejd.2019.3576 DOI: https://doi.org/10.1684/ejd.2019.3576
Van Voorhees AS, Stein Gold L, Lebwohl M, et al. Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: Results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind study. J Am Acad Dermatol. 2020;83(1):96-103. doi:10.1016/j.jaad.2020.01.072 DOI: https://doi.org/10.1016/j.jaad.2020.01.072
Piantoni S, Colombo E, Tincani A, Airò P, Scarsi M. Predictive factors of abatacept therapy discontinuation in patients with rheumatoid arthritis. Clin Rheumatol. 2016;35(4):1065-1069. doi:10.1007/s10067-016-3185-1 DOI: https://doi.org/10.1007/s10067-016-3185-1
Moreland L, Bate G, Kirkpatrick P. Abatacept. Nat Rev Drug Discov. 2006;5(3):185-186. doi:10.1038/nrd1989 DOI: https://doi.org/10.1038/nrd1989
Mackay-Wiggan J, Sallee BN, Wang EHC, et al. An open-label study evaluating the efficacy of abatacept in alopecia areata. J Am Acad Dermatol. 2021;84(3):841-844. doi:10.1016/j.jaad.2020.09.091 DOI: https://doi.org/10.1016/j.jaad.2020.09.091
Frye BC, Rump IC, Uhlmann A, et al. Safety and efficacy of abatacept in patients with treatment-resistant SARCoidosis (ABASARC) - protocol for a multi-center, single-arm phase IIa trial. Contemp Clin Trials Commun. 2020;19:100575. Published 2020 May 29. doi:10.1016/j.conctc.2020.100575 DOI: https://doi.org/10.1016/j.conctc.2020.100575
Harb H, Chatila TA. Mechanisms of Dupilumab. Clin Exp Allergy. 2020;50(1):5-14. doi:10.1111/cea.13491 DOI: https://doi.org/10.1111/cea.13491
Beck LA, Thaçi D, Hamilton JD, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014;371(2):130-139. doi:10.1056/NEJMoa1314768 DOI: https://doi.org/10.1056/NEJMoa1314768
Kulkarni M, Rohan CA, Travers JB, Serrao R. Long-Term Efficacy of Dupilumab in Alopecia Areata. Am J Case Rep. 2022;23:e936488. Published 2022 Jun 21. doi:10.12659/AJCR.936488 DOI: https://doi.org/10.12659/AJCR.936488
Aszodi N, Pumnea T, Wollenberg A. Dupilumab-asssoziierte Abheilung einer Alopecia areata bei Atopischem Ekzem [Dupilumab-Associated Healing of Alopecia Areata in an Atopic Dermatitis Patient]. Dtsch Med Wochenschr. 2019;144(9):602-605. doi:10.1055/a-0836-3119 DOI: https://doi.org/10.1055/a-0836-3119
Ludriksone L, Elsner P, Schliemann S. Simultaneous effectiveness of dupilumab in atopic dermatitis and alopecia areata in two patients. J Dtsch Dermatol Ges. 2019;17(12):1278-1280. doi:10.1111/ddg.13990 DOI: https://doi.org/10.1111/ddg.13990
Patruno C, Napolitano M, Ferrillo M, Fabbrocini G. Dupilumab and alopecia: A Janus effect. Dermatol Ther. 2019;32(5):e13023. doi:10.1111/dth.13023 DOI: https://doi.org/10.1111/dth.13023
Uchida H, Kamata M, Watanabe A, et al. Dupilumab Improved Alopecia Areata in a Patient with Atopic Dermatitis: A Case Report. Acta Derm Venereol. 2019;99(7):675-676. doi:10.2340/00015555-3183 DOI: https://doi.org/10.2340/00015555-3183
Magdaleno-Tapial J, Valenzuela-Oñate C, García-Legaz-Martínez M, Martínez-Domenech Á, Pérez-Ferriols A. Improvement of alopecia areata with Dupilumab in a patient with severe atopic dermatitis and review the literature. Australas J Dermatol. 2020;61(2):e223-e225. doi:10.1111/ajd.13208 DOI: https://doi.org/10.1111/ajd.13208
Smogorzewski J, Sierro T, Compoginis G, Kim G. Remission of alopecia universalis in a patient with atopic dermatitis treated with dupilumab. JAAD Case Rep. 2019;5(2):116-117. Published 2019 Jan 12. doi:10.1016/j.jdcr.2018.11.007 DOI: https://doi.org/10.1016/j.jdcr.2018.11.007
Darrigade AS, Legrand A, Andreu N, et al. Dual efficacy of dupilumab in a patient with concomitant atopic dermatitis and alopecia areata. Br J Dermatol. 2018;179(2):534-536. doi:10.1111/bjd.16711 DOI: https://doi.org/10.1111/bjd.16711
Alniemi DT, McGevna L. Dupilumab treatment for atopic dermatitis leading to unexpected treatment for alopecia universalis. JAAD Case Rep. 2019;5(2):111-112. Published 2019 Jan 11. doi:10.1016/j.jdcr.2018.11.006 DOI: https://doi.org/10.1016/j.jdcr.2018.11.006
Sevray M, Dupré D, Misery L, Abasq-Thomas C. Hair regrowth and dissemination of molluscum contagiosum: two unexpected effects with dupilumab. J Eur Acad Dermatol Venereol. 2019;33(8):e296-e298. doi:10.1111/jdv.15571 DOI: https://doi.org/10.1111/jdv.15571
Gruenstein D, Malik K, Levitt J. Full scalp hair regrowth in a 4-year-old girl with alopecia areata and atopic dermatitis treated with dupilumab. JAAD Case Rep. 2020;6(12):1286-1287. Published 2020 Oct 15. doi:10.1016/j.jdcr.2020.10.010 DOI: https://doi.org/10.1016/j.jdcr.2020.10.010
Guttman-Yassky E, Renert-Yuval Y, Bares J, et al. Phase 2a randomized clinical trial of dupilumab (anti-IL-4Rα) for alopecia areata patients. Allergy. 2022;77(3):897-906. doi:10.1111/all.15071 DOI: https://doi.org/10.1111/all.15071
Barbarin C, Hosteing S, Nosbaum A, Allouchery M, Celerier P. Early onset of alopecia areata after dupilumab introduction in a patient with atopic dermatitis. Eur J Dermatol. 2019;29(5):542-543. doi:10.1684/ejd.2019.3626 DOI: https://doi.org/10.1684/ejd.2019.3626
Barroso-García B, Rial MJ, Molina A, Sastre J. Alopecia Areata in Severe Atopic Dermatitis Treated With Dupilumab. J Investig Allergol Clin Immunol. 2018;28(6):420-421. doi:10.18176/jiaci.0301 DOI: https://doi.org/10.18176/jiaci.0301
Flanagan K, Sperling L, Lin J. Drug-induced alopecia after dupilumab therapy. JAAD Case Rep. 2018;5(1):54-56. Published 2018 Dec 6. doi:10.1016/j.jdcr.2018.10.010 DOI: https://doi.org/10.1016/j.jdcr.2018.10.010
Mitchell K, Levitt J. Alopecia areata after dupilumab for atopic dermatitis. JAAD Case Rep. 2018;4(2):143-144. Published 2018 Jan 16. doi:10.1016/j.jdcr.2017.11.020 DOI: https://doi.org/10.1016/j.jdcr.2017.11.020
D'Ippolito D, Pisano M. Dupilumab (Dupixent): An Interleukin-4 Receptor Antagonist for Atopic Dermatitis. P T. 2018;43(9):532-535.
Sands BE, Sandborn WJ, Panaccione R, et al. Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med. 2019;381(13):1201-1214. doi: 0.1056/NEJMoa1900750 DOI: https://doi.org/10.1056/NEJMoa1900750
Ghosh S, Gensler LS, Yang Z, et al. Ustekinumab Safety in Psoriasis, Psoriatic Arthritis, and Crohn's Disease: An Integrated Analysis of Phase II/III Clinical Development Programs [published correction appears in Drug Saf. 2019 Apr 22;:]. Drug Saf. 2019;42(6):751-768. doi:10.1007/s40264-019-00797-3 DOI: https://doi.org/10.1007/s40264-019-00797-3
Guttman-Yassky E, Ungar B, Noda S, et al. Extensive alopecia areata is reversed by IL-12/IL-23p40 cytokine antagonism. J Allergy Clin Immunol. 2016;137(1):301-304. doi:10.1016/j.jaci.2015.11.001 DOI: https://doi.org/10.1016/j.jaci.2015.11.001
Aleisa A, Lim Y, Gordon S, et al. Response to ustekinumab in three pediatric patients with alopecia areata. Pediatr Dermatol. 2019;36(1):e44-e45. doi:10.1111/pde.13699 DOI: https://doi.org/10.1111/pde.13699
Ortolan LS, Kim SR, Crotts S, et al. IL-12/IL-23 neutralization is ineffective for alopecia areata in mice and humans. The Journal of Allergy and Clinical Immunology. 2019 Dec;144(6):1731-1734.e1. DOI: 10.1016/j.jaci.2019.08.014 DOI: https://doi.org/10.1016/j.jaci.2019.08.014
Tauber M, Beneton N, Reygagne P, Bachelez H, Viguier M. Alopecia areata developing during ustekinumab therapy: report of two cases. Eur J Dermatol. 2013;23(6):912-913. doi:10.1684/ejd.2013.2221 DOI: https://doi.org/10.1684/ejd.2013.2221
Słowińska M, Kardynal A, Warszawik O, Czuwara J, Rudnicka L. Alopecia areata developing paralell to improvement of psoriasis during ustekinumab therapy. J Dermatol Case Rep. 2010;4(1):15-17. doi:10.3315/jdcr.2010.1041 DOI: https://doi.org/10.3315/jdcr.2010.1041
Verros C, Rallis E, Crowe M. Letter: Alopecia areata during ustekinumab administration: Co-existence or an adverse reaction?. Dermatol Online J. 2012;18(7):14. Published 2012 Jul 15. DOI: https://doi.org/10.5070/D34G31C0TM
Mirouse A, Barete S, Desbois AC, et al. Long-Term Outcome of Ustekinumab Therapy for Behçet's Disease. Arthritis Rheumatol. 2019;71(10):1727-1732. DOI: https://doi.org/10.1002/art.40912
Hajar T, Gontijo JRV, Hanifin JM. New and developing therapies for atopic dermatitis. An Bras Dermatol. 2018;93(1):104-107. doi:10.1590/abd1806-4841.20187682 DOI: https://doi.org/10.1590/abd1806-4841.20187682
Guttman E., A Pilot Study of Tralokinumab in Subjects With Moderate to Severe Alopecia Areata - NCT02684097 (2020). https://clinicaltrials.gov/ct2/show/results/NCT02684097 [acess: 23.11.2022]
Wollenberg A, Howell MD, Guttman-Yassky E, et al. Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb. J Allergy Clin Immunol. 2019;143(1):135-141. doi:10.1016/j.jaci.2018.05.029 DOI: https://doi.org/10.1016/j.jaci.2018.05.029
Secukinumab. In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; March 15, 2021.
Guttman-Yassky E, Nia JK, Hashim PW, et al. Efficacy and safety of secukinumab treatment in adults with extensive alopecia areata. Arch Dermatol Res. 2018;310(8):607-614. doi:10.1007/s00403-018-1853-5 DOI: https://doi.org/10.1007/s00403-018-1853-5
Yalici Armagan B, Atakan N. New onset alopecia areata during secukinumab therapy. Dermatol Ther. 2019;32(5):e13071. doi:10.1111/dth.13071 DOI: https://doi.org/10.1111/dth.13071
Aboobacker S, Kurn H, Al Aboud AM. Secukinumab. In: StatPearls. Treasure Island (FL): StatPearls Publishing; July 6, 2022.
Tauber M, Buche S, Reygagne P, et al. Alopecia areata occurring during anti-TNF therapy: a national multicenter prospective study. J Am Acad Dermatol. 2014;70(6):1146-1149. doi:10.1016/j.jaad.2014.03.005 DOI: https://doi.org/10.1016/j.jaad.2014.03.005
Kandpal R. Alopecia Universalis in a Case of Rheumatoid Arthritis after Treatment with Etanercept. Int J Trichology. 2019;11(4):173-176. doi:10.4103/ijt.ijt_22_19 DOI: https://doi.org/10.4103/ijt.ijt_22_19
Strober BE, Menon K, McMichael A, et al. Alefacept for severe alopecia areata: a randomized, double-blind, placebo-controlled study. Arch Dermatol. 2009;145(11):1262-1266. doi:10.1001/archdermatol.2009.264 DOI: https://doi.org/10.1001/archdermatol.2009.264
Price VH, Hordinsky MK, Olsen EA, et al. Subcutaneous efalizumab is not effective in the treatment of alopecia areata. J Am Acad Dermatol. 2008;58(3):395-402. doi:10.1016/j.jaad.2007.10.645 DOI: https://doi.org/10.1016/j.jaad.2007.10.645
Magen E. Alopecia Areata after Omalizumab Treatment for Chronic Spontaneous Urticaria. Acta Derm Venereol. 2019;99(10):919-920. doi:10.2340/00015555-3244 DOI: https://doi.org/10.2340/00015555-3244
Eldirany SA, Myung P, Bunick CG. Ixekizumab-induced alopecia areata. JAAD Case Rep. 2019;6(1):51-53. Published 2019 Dec 26. doi:10.1016/j.jdcr.2019.10.012 DOI: https://doi.org/10.1016/j.jdcr.2019.10.012
Yajima M, Akeda T, Kondo M, Habe K, Yamanaka K. Alopecia Diffusa while Using Interleukin-17 Inhibitors against Psoriasis Vulgaris. Case Rep Dermatol. 2019;11(1):82-85. Published 2019 Mar 28. doi:10.1159/000499030 DOI: https://doi.org/10.1159/000499030
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Maciej Stępień, Stanisław Anczyk
This work is licensed under a Creative Commons Attribution 4.0 International License.
For all articles published in Prospects in Pharmaceutical Sciences copyright is retained by the authors. The journal publishes articles in the Open Access policy, within the CC BY 4.0 licence.
This is a human-readable summary of (and not a substitute for) the license. Disclaimer.
You are free to:
Share — copy and redistribute the material in any medium or format
Adapt — remix, transform, and build upon the material for any purpose, even commercially.
The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation.
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
How to Cite
